Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
ICEC0942 is a cyclin-dependent kinase 7 (Cdk7) inhibitor (IC50 = 0.04 µM).1 It is selective for Cdk7 over Cdk1, -2, -4, -5, -6, and -9 (IC50s = 1.8, 0.62, 49, 9.4, 34, and 1.2 µM, respectively). ICEC0942 induces cell cycle arrest at the G2/M phase and apoptosis in HCT116 cells when used at concentrations of 1 and 10 µM. In vivo, ICEC0942 (100 mg/kg) reduces tumor growth in MCF-7 and HCT116 mouse xenograft models.
WARNING This product is not for human or veterinary use.
1. ICEC0942, an orally bioavailable selective inhibitor of CDK7 for cancer treatment. Mol. Cancer Ther. 17(6), 1156-1166 (2018).